Aptose Biosciences Company Profile (NASDAQ:APTO)

About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APTO
  • CUSIP: N/A
  • Web: www.aptose.com
Capitalization:
  • Market Cap: $33.28 million
  • Outstanding Shares: 21,753,000
Average Prices:
  • 50 Day Moving Avg: $1.29
  • 200 Day Moving Avg: $1.14
  • 52 Week Range: $0.78 - $3.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.43 per share
  • Price / Book: 3.56
Profitability:
  • EBIDTA: ($14,230,000.00)
  • Return on Equity: -174.74%
  • Return on Assets: -146.38%
Debt:
  • Current Ratio: 5.33%
  • Quick Ratio: 5.33%
Misc:
  • Average Volume: 500,798 shs.
  • Beta: 1.62
  • Short Ratio: 1.78
 
Frequently Asked Questions for Aptose Biosciences (NASDAQ:APTO)

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences, Inc. (NASDAQ:APTO) posted its quarterly earnings data on Tuesday, March, 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. View Aptose Biosciences' Earnings History.

Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2017?

5 brokerages have issued twelve-month price targets for Aptose Biosciences' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptose Biosciences' stock price to reach $9.00 in the next year. View Analyst Ratings for Aptose Biosciences.

What are analysts saying about Aptose Biosciences stock?

Here are some recent quotes from research analysts about Aptose Biosciences stock:

  • 1. Canaccord Genuity analysts commented, "CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18." (5/12/2017)
  • 2. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (11/17/2016)

Who are some of Aptose Biosciences' key competitors?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:

  • William Glenn Rice, Chairman of the Board, President, Chief Executive Officer
  • Gregory Kwok Lee Chow, Chief Financial Officer, Senior Vice President
  • Denis R. Burger Ph.D., Independent Director
  • Erich M. Platzer M.D., Ph.D., Independent Director
  • Bradley Thompson, Independent Director
  • Mark D. Vincent M.D., Independent Director
  • Warren Whitehead, Independent Director

How do I buy Aptose Biosciences stock?

Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of Aptose Biosciences stock can currently be purchased for approximately $1.53.


MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $9.00 (488.24% upside)

Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017HC WainwrightInitiated CoverageHoldHighView Rating Details
6/8/2017Rodman & RenshawInitiated CoverageNeutral -> NeutralHighView Rating Details
5/12/2017Canaccord GenuityReiterated RatingBuy$7.00LowView Rating Details
11/16/2016Royal Bank Of CanadaLower Price TargetOutperform$18.00 -> $12.00N/AView Rating Details
10/14/2016Roth CapitalReiterated RatingBuy$8.00N/AView Rating Details
6/9/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Aptose Biosciences (NASDAQ:APTO)
Earnings by Quarter for Aptose Biosciences (NASDAQ:APTO)
Earnings History by Quarter for Aptose Biosciences (NASDAQ APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.31)($0.22)ViewN/AView Earnings Details
3/3/2015Q4 2014($0.31)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-1.17 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Aptose Biosciences (NASDAQ:APTO)
Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
Source:
DateHeadline
businesswire.com logoReviva Pharmaceuticals Announces Addition of a New Member to its Board of Directors
www.businesswire.com - July 23 at 1:57 AM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - July 13 at 8:29 AM
prnewswire.com logoProstate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 3:22 PM
americanbankingnews.com logoAptose Biosciences, Inc. (APTO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 10:02 AM
americanbankingnews.com logo Analysts Anticipate Aptose Biosciences, Inc. (APTO) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - June 19 at 9:42 AM
americanbankingnews.com logoAptose Biosciences Inc (APTO) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - June 11 at 9:02 AM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For June 8, 2017 - Benzinga
www.benzinga.com - June 9 at 2:21 AM
americanbankingnews.com logoAptose Biosciences Inc (APTO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 8 at 9:06 AM
americanbankingnews.com logoAptose Biosciences Inc (APTO) Coverage Initiated by Analysts at Rodman & Renshaw
www.americanbankingnews.com - June 8 at 7:38 AM
globenewswire.com logoAptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:41 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: May 11 - StreetInsider.com
www.streetinsider.com - May 12 at 4:10 PM
americanbankingnews.com logoAptose Biosciences Inc (APTO) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - May 12 at 4:05 PM
finance.yahoo.com logoInvestor Network: Aptose Biosciences Inc. to Host Earnings Call
finance.yahoo.com - May 12 at 2:04 AM
finance.yahoo.com logoAptose Reports Results for the First Quarter Ended March 31, 2017
finance.yahoo.com - May 12 at 2:04 AM
globenewswire.com logoAptose Reports Results for the First Quarter Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 11 at 9:03 PM
globenewswire.com logoPreclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented at AACR Hematologic Malignancies ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 8:34 PM
americanbankingnews.com logoAptose Biosciences Inc (APTO) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 8 at 8:52 AM
americanbankingnews.com logoAptose Biosciences (APTO) Receiving Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 29 at 9:56 AM
americanbankingnews.com logoAptose Biosciences (APTO) Receives Media Impact Score of 0.56
www.americanbankingnews.com - April 26 at 11:40 AM
finance.yahoo.com logoAptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017 - Yahoo Finance
finance.yahoo.com - April 25 at 3:34 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: Apr 25 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - April 25 at 3:34 PM
finance.yahoo.com logoAptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017
finance.yahoo.com - April 25 at 10:12 AM
finance.yahoo.com logoAptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017
finance.yahoo.com - April 24 at 10:41 AM
globenewswire.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting - GlobeNewswire (press release)
www.globenewswire.com - April 20 at 1:42 AM
globenewswire.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic ... - GlobeNewswire (press release)
globenewswire.com - April 19 at 3:38 PM
feeds.benzinga.com logoAptose Biosciences to Present CG'806 Data at AACR Hematologic Malignancies Meeting
feeds.benzinga.com - April 19 at 8:58 AM
finance.yahoo.com logoAptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
finance.yahoo.com - April 19 at 8:32 AM
americanbankingnews.com logoAptose Biosciences (APTO) Earns Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 15 at 9:45 AM
us.rd.yahoo.com logoAptose Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 28 at 8:37 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences - PR Newswire (press release)
www.prnewswire.com - March 27 at 8:12 AM
streetinsider.com logoAptose Biosciences (APTO) Announces Planned Departure of CBO Avanish Vellanki - StreetInsider.com
www.streetinsider.com - March 27 at 8:12 AM
seekingalpha.com logoAptose Biosciences (APTO) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 3:58 PM
feeds.benzinga.com logoAptose to Participate in Upcoming Investor Conferences
feeds.benzinga.com - March 2 at 7:54 AM
nasdaq.com logoAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day - Nasdaq
www.nasdaq.com - February 2 at 3:38 PM
finance.yahoo.com logoAptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day
finance.yahoo.com - February 2 at 3:38 PM
investopedia.com logoAptose Delays Lead Cancer Drug Development (APTO)
www.investopedia.com - January 27 at 4:25 PM
investopedia.com logoAptose Shifts Focus, Delays Cancer Drug Development
www.investopedia.com - January 27 at 4:25 PM
streetinsider.com logoAptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253
www.streetinsider.com - January 23 at 8:50 PM
us.rd.yahoo.com logo7:02 am Aptose Biosciences will temporarily delay clinical activities with APTO-253 in order to elucidate the cause of recent manufacturing setbacks related to the intravenous formulation of APTO-253
us.rd.yahoo.com - January 23 at 8:50 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: Jan 23 - StreetInsider.com
www.streetinsider.com - January 23 at 3:40 PM

Social

Chart

Aptose Biosciences (APTO) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff